BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20156119)

  • 1. Biological characterization of ADAM22 variants reveals the importance of a disintegrin domain sequence in cell surface expression.
    Sagane K; Sugimoto H; Akaike A
    J Recept Signal Transduct Res; 2010 Apr; 30(2):72-7. PubMed ID: 20156119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11.
    Sagane K; Ishihama Y; Sugimoto H
    Int J Biol Sci; 2008; 4(6):387-96. PubMed ID: 18974846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling.
    Ozkaynak E; Abello G; Jaegle M; van Berge L; Hamer D; Kegel L; Driegen S; Sagane K; Bermingham JR; Meijer D
    J Neurosci; 2010 Mar; 30(10):3857-64. PubMed ID: 20220021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of mutations in the LGI1 receptor ADAM22 gene in autosomal dominant lateral temporal epilepsy.
    Chabrol E; Gourfinkel-An I; Scheffer IE; Picard F; Couarch P; Berkovic SF; McMahon JM; Bajaj N; Mota-Vieira L; Mota R; Trouillard O; Depienne C; Baulac M; LeGuern E; Baulac S
    Epilepsy Res; 2007 Aug; 76(1):41-8. PubMed ID: 17681454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient ADAM22 surface expression is mediated by phosphorylation-dependent interaction with 14-3-3 protein family members.
    Gödde NJ; D'Abaco GM; Paradiso L; Novak U
    J Cell Sci; 2006 Aug; 119(Pt 16):3296-305. PubMed ID: 16868027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission.
    Fukata Y; Adesnik H; Iwanaga T; Bredt DS; Nicoll RA; Fukata M
    Science; 2006 Sep; 313(5794):1792-5. PubMed ID: 16990550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22.
    Yamagata A; Miyazaki Y; Yokoi N; Shigematsu H; Sato Y; Goto-Ito S; Maeda A; Goto T; Sanbo M; Hirabayashi M; Shirouzu M; Fukata Y; Fukata M; Fukai S
    Nat Commun; 2018 Apr; 9(1):1546. PubMed ID: 29670100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional phylogenetic analysis of LGI proteins identifies an interaction motif crucial for myelination.
    Kegel L; Jaegle M; Driegen S; Aunin E; Leslie K; Fukata Y; Watanabe M; Fukata M; Meijer D
    Development; 2014 Apr; 141(8):1749-56. PubMed ID: 24715463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential coding potential of ADAM22 mRNAs.
    Gödde NJ; D'Abaco GM; Paradiso L; Novak U
    Gene; 2007 Nov; 403(1-2):80-8. PubMed ID: 17884303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain.
    D'Abaco GM; Ng K; Paradiso L; Godde NJ; Kaye A; Novak U
    Neurosurgery; 2006 Jan; 58(1):179-86; discussion 179-86. PubMed ID: 16385342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LGI1-ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function.
    Lovero KL; Fukata Y; Granger AJ; Fukata M; Nicoll RA
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4129-37. PubMed ID: 26178195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.
    Ohkawa T; Fukata Y; Yamasaki M; Miyazaki T; Yokoi N; Takashima H; Watanabe M; Watanabe O; Fukata M
    J Neurosci; 2013 Nov; 33(46):18161-74. PubMed ID: 24227725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice.
    Sagane K; Hayakawa K; Kai J; Hirohashi T; Takahashi E; Miyamoto N; Ino M; Oki T; Yamazaki K; Nagasu T
    BMC Neurosci; 2005 May; 6():33. PubMed ID: 15876356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAM22 plays an important role in cell adhesion and spreading with the assistance of 14-3-3.
    Zhu P; Sang Y; Xu H; Zhao J; Xu R; Sun Y; Xu T; Wang X; Chen L; Feng H; Li C; Zhao S
    Biochem Biophys Res Commun; 2005 Jun; 331(4):938-46. PubMed ID: 15882968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.
    Ramberger M; Berretta A; Tan JMM; Sun B; Michael S; Yeo T; Theorell J; Bashford-Rogers R; Paneva S; O'Dowd V; Dedi N; Topia S; Griffin R; Ramirez-Franco J; El Far O; Baulac S; Leite MI; Sen A; Jeans A; McMillan D; Marshall D; Anthony D; Lightwood D; Waters P; Irani SR
    Brain; 2020 Jun; 143(6):1731-1745. PubMed ID: 32437528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion.
    Gobeil S; Letartre L; Raymond V
    Exp Eye Res; 2006 Jun; 82(6):1017-29. PubMed ID: 16466712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy.
    van der Knoop MM; Maroofian R; Fukata Y; van Ierland Y; Karimiani EG; Lehesjoki AE; Muona M; Paetau A; Miyazaki Y; Hirano Y; Selim L; de França M; Fock RA; Beetz C; Ruivenkamp CAL; Eaton AJ; Morneau-Jacob FD; Sagi-Dain L; Shemer-Meiri L; Peleg A; Haddad-Halloun J; Kamphuis DJ; Peeters-Scholte CMPCD; Kurul SH; Horvath R; Lochmüller H; Murphy D; Waldmüller S; Spranger S; Overberg D; Muir AM; Rad A; Vona B; Abdulwahad F; Maddirevula S; Povolotskaya IS; Voinova VY; Gowda VK; Srinivasan VM; Alkuraya FS; Mefford HC; Alfadhel M; Haack TB; Striano P; Severino M; Fukata M; Hilhorst-Hofstee Y; Houlden H
    Brain; 2022 Jul; 145(7):2301-2312. PubMed ID: 35373813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification and insights into structure and folding of the ADAM22 pro domain.
    Sørensen HP; Jacobsen J; Nielbo S; Poulsen FM; Wewer UM
    Protein Expr Purif; 2008 Oct; 61(2):175-83. PubMed ID: 18593599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer.
    Bolger JC; Young LS
    Vitam Horm; 2013; 93():307-21. PubMed ID: 23810013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADPEAF mutations reduce levels of secreted LGI1, a putative tumor suppressor protein linked to epilepsy.
    Senechal KR; Thaller C; Noebels JL
    Hum Mol Genet; 2005 Jun; 14(12):1613-20. PubMed ID: 15857855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.